Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway.

ABSTRACT:

Background and aims

Intravenous iron therapies contain iron-carbohydrate complexes, designed to ensure iron becomes bioavailable via the intermediary of spleen and liver reticuloendothelial macrophages. How other tissues obtain and handle this iron remains unknown. This study addresses this question in the context of the heart.

Methods

A prospective observational study was conducted in 12 patients receiving ferric carboxymaltose (FCM) for iron deficiency. Myocardial, spleen, and liver magnetic resonance relaxation times and plasma iron markers were collected longitudinally. To examine the handling of iron taken up by the myocardium, intracellular labile iron pool (LIP) was imaged in FCM-treated mice and cells.

Results

In patients, myocardial relaxation time T1 dropped

SUBMITTER: Vera-Aviles M 

PROVIDER: S-EPMC11544312 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature